الفهرس 
Viral
HemochromatosisOnly 14 pages are availabe for public view
 |  | from | 200 |  |  |
| | | from | 200 | | |
Abstract
Introduction: Despite the great success of living donor liver transplantation in management of patients with end stage liver disease; fulminant liver failure or neoplastic liver disorders yet, serious medical and surgical complications may occurs. Recurrence of the primary liver disease is still the most common complication after LDLT especially viral hepatitis C. In general, there are three forms of post liver transplantation HCV disease: acute recurrence, chronic recurrence and a rare, primarily cholestatic disease called fibrosing cholestatic hepatitis (FCH). Many interventions to prevent, improve or halt the recurrence of HCV infection have been evaluated. However, the results depends on the definition of recurrent hepatitis, timing of administration of anti-HCV therapy relative to transplantation, drugs used and the dose of these drugs. There are three potential alternatives or complementary approaches: (1) preemptive antiviral therapy as the patient is awaiting the availability of an organ donor, (2) early post-transplant antiviral therapy before histological damage has occurred and (3) treatment of disease when it occurs. Approximately 20% to 30% of patients undergoing liver transplantation for autoimmune hepatitis develop features of recurrent disease. Diagnostic criteria for recurrent AIH are similar to those used in the non-transplanted liver. Prednisone alone or in combination with azathioprine remains the mainstay therapy for recurrent or de novo autoimmune hepatitis after transplantation, and it is typically added to the existing immunosuppressive regimen. Aim of work: The aim of this study was to report the medical complications that may occur after living donor liver transplantation. Also, post-transplantation prevention and management of these complications which could improve the success and applicability of this procedure. Conclusions: The majority of skin tumors in LT are accounted for by skin carcinomas (95%), followed by Kaposi’s sarcoma and melanoma. Other rare skin tumors (such as Merkel cell carcinoma and anogenital cancers), known to be increased in transplant patients. Skin carcinoma involves multiple intrinsic and extrinsic factors including mainly sun exposure and immunosuppressive treatment. Intrinsic factors include higher age at transplantation, male sex, fair skin type, fair eyes, red hair and several genetic factors. Post-transplant lymphoproliferative disorders are a relatively common malignancy after transplantation and is seen in up to 10% of all solid organ transplant recipients. And, about 1-2.8% of liver transplant.